Well-Funded to De-Risk Innovative Assets & Create New Companies
Cydan works with leading investors in the life sciences space. The accelerator launched in 2013 with $26 million in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures and Bay City Capital with participation from Alexandria Real Estate Equities, Inc./Alexandria Venture Investments.
New Enterprise Associates, Inc.
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With more than $13 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record includes more than 175 portfolio company IPOs and more than 290 acquisitions. In the U.S., NEA has offices in the Washington, D.C. metropolitan area; Menlo Park, California; and New York City. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.
Pfizer Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of Worldwide Business Development, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck. For more information, visit www.lundbeckfondventures.com.
Bay City Capital
Bay City Capital is a life sciences venture capital firm investing in opportunities across the various life sciences sectors in companies at all stages of development. Established in 1997, the firm has managed eight venture capital funds representing over $1.6 billion in capital commitments. Bay City Capital has invested in over 100 life sciences companies globally, including Epizyme, Epocrates, GenturaDx, Hyperion Therapeutics, IDev Technologies, Ion Torrent Systems, Lexicon, MAP Pharmaceuticals, Medarex, NextWave Pharmaceuticals, Oculex Pharmaceuticals, Pharmion, Reliant Pharmaceuticals and Sunesis Pharmaceuticals. For more information, visit www.baycitycapital.com.
Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
Alexandria Real Estate Equities, Inc./Alexandria Venture Investments (NYSE: ARE), is the largest and leading investment-grade real estate investment trust (REIT) focused principally on owning, operating and developing high-quality, sustainable real estate for the broad and diverse life science industry. Founded in 1994, Alexandria was the first REIT to identify and pursue the laboratory niche and has since had the first-mover advantage in best-in-class life science cluster locations. In 1996, Alexandria founded Alexandria Venture Investments, its strategic venture capital arm that actively invests at the cutting edge of novel, breakthrough discoveries in biopharmaceuticals, technology platforms, clinical candidates, diagnostics, research tools and medical devices. Alexandria is uniquely positioned to fund life science and advanced technology companies based on its experience and in-depth understanding of the life science industry, its long-term relationships with leading investors and its world-class international scientific advisory network. For more information, please visit www.are.com.